TDC
EW icon

Thompson Davis & Co’s Edwards Lifesciences EW Stock Holding History

Thompson Davis & Co’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-525
Closed -$16K – 1175
2016
Q4 		$16K Buy
525
+108
+26% +$3.5K 0.03% 563
2016
Q3 		$17K Buy
+417
New +$15.7K 0.03% 528
2015
Q3 		– Sell
-4,890
Closed -$116K – 1166
2015
Q2 		$116K Buy
4,890
+360
+8% +$8.12K 0.13% 174
2015
Q1 		$108K Buy
+4,530
New +$102K 0.13% 171

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $29.1B AUM 43.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Thompson Davis & Co's EW Position: Q1 2017 in Review

Thompson Davis & Co sold out of Edwards Lifesciences (EW) in Q1 2017, closing a stake of 525 shares — an estimated $16K sold.

Thompson Davis & Co first reported a position in EW in Q1 2015 and held it in 4 quarters. The position peaked at $116K in Q2 2015. 691 funds tracked by Wall St. Rank hold EW as of Q1 2017.

  • Thompson Davis & Co reported no remaining Edwards Lifesciences position as of Q1 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 525 Edwards Lifesciences shares in Q1 2017, an estimated $16K.
  • Thompson Davis & Co first reported a position in Edwards Lifesciences in Q1 2015 and held it in 4 quarters.
  • Thompson Davis & Co's Edwards Lifesciences position peaked at $116K in Q2 2015.
  • 691 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2017.

Based on Thompson Davis & Co's 13F filing for Q1 2017, filed 8 May 2017.